Eleni Pittas

Experience: Representative Matters: Advised Quickbase, Inc. (a portfolio company of Vista Equity Partners) on its acquisition of CloudPipes, a UK and Bulgarian provider of cloud-based integration and automation platforms.; Represented Black Dragon Capital in connection with its acquisition of Grass Valley, a leading technology supplier of advanced broadcast and media solutions, with operations in over 20 different jurisdictions worldwide.; Advised AstraZeneca AB on its agreement with Grunenthal to divest the European rights to Nexium for an upfront payment of $700 million with further sales-related and milestone payments of up to $90 million.; Advised AstraZeneca AB on its agreement with Grunenthal to divest the global rights to Vimovo in all markets excluding the United States and Japan for an upfront payment of $115 million and further payments up to another $17 million.; Advised AstraZeneca AB on its US$243 million divestment to Cheplapharm of the global rights (excluding China, Japan, USA, and Mexico) for LOSEC (omeprazole) and associated brands.; Advised AstraZeneca AB on its US$236 million sale of Atacand to German pharma company Cheplapharm Arzneimittel. Atacand is a prescription medicine for the treatment of heart failure and hypertension.; Advised Rentokil Initial on the CMA mandated divestment of part of the MPCL Limited business to Rentokil Initial and subsequent sale of MPCL Limited to ServiceMaster.; Advised AB Volvo in the sale of 75.1% of the issued shares in WirelessCar Sweden AB (an automotive telematics company) by Volvo Information Technology AB to Volkswagen Finance Luxemburg SA.